BRIEF-Bioventus Inc - Plans Limited Release Of Talismann And Stimtrial In Some U.S. Markets In Q3

Reuters
30 Jul
BRIEF-Bioventus Inc - Plans Limited Release Of Talismann And Stimtrial In Some U.S. Markets In Q3

July 30 (Reuters) - Bioventus Inc BVS.O:

  • BIOVENTUS RECEIVES FDA 510$(K)$ CLEARANCES FOR TWO NEXT-GENERATION PERIPHERAL NERVE STIMULATION PRODUCTS

  • BIOVENTUS INC - PLANS LIMITED RELEASE OF TALISMANN AND STIMTRIAL IN SOME U.S. MARKETS IN Q3

Source text: ID:nGNX78Kwsk

Further company coverage: BVS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10